Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences. Details of the events are below:
Live webcasts will be available in the investor section of the company's website at www.epizyme.com. The webcasts will be archived for 60 days following the call and presentations.
About Epizyme, Inc.
Epizyme, Inc. is a late-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK™ (tazemetostat), for the treatment of patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication is contingent upon verification and description of clinical benefit in an ongoing confirmatory trial. The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218005143/en/
Media:
Erin Graves, Epizyme, Inc.
[email protected]
(617) 500-0615
Investors:
Alicia Davis, THRUST Strategic Communications
[email protected]
(910) 620-3302